151 related articles for article (PubMed ID: 27424036)
1. Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: a dose ranging, randomized, placebo-controlled, crossover study.
Fleishaker DL; Mukherjee A; Whaley FS; Daniel S; Zeiher BG
BMC Musculoskelet Disord; 2016 Jul; 17():293. PubMed ID: 27424036
[TBL] [Abstract][Full Text] [Related]
2. Dissociated Agonist of Glucocorticoid Receptor or Prednisone for Active Rheumatoid Arthritis: Effects on P1NP and Osteocalcin Pharmacodynamics.
Shoji S; Suzuki A; Conrado DJ; Peterson MC; Hey-Hadavi J; McCabe D; Rojo R; Tammara BK
CPT Pharmacometrics Syst Pharmacol; 2017 Jul; 6(7):439-448. PubMed ID: 28556506
[TBL] [Abstract][Full Text] [Related]
3. The osteoblast: Linking glucocorticoid-induced osteoporosis and hyperglycaemia? A post-hoc analysis of a randomised clinical trial.
van Bommel EJM; de Jongh RT; Brands M; Heijboer AC; den Heijer M; Serlie MJ; van Raalte DH
Bone; 2018 Jul; 112():173-176. PubMed ID: 29729427
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
5. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
6. Effects of low-dose prednisone on bone metabolism.
Ton FN; Gunawardene SC; Lee H; Neer RM
J Bone Miner Res; 2005 Mar; 20(3):464-70. PubMed ID: 15746991
[TBL] [Abstract][Full Text] [Related]
7. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study.
Karsdal MA; Byrjalsen I; Henriksen K; Riis BJ; Lau EM; Arnold M; Christiansen C
Osteoarthritis Cartilage; 2010 Feb; 18(2):150-9. PubMed ID: 19747581
[TBL] [Abstract][Full Text] [Related]
8. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
[TBL] [Abstract][Full Text] [Related]
9. Octreotide abolishes the acute decrease in bone turnover in response to oral glucose.
Clowes JA; Allen HC; Prentis DM; Eastell R; Blumsohn A
J Clin Endocrinol Metab; 2003 Oct; 88(10):4867-73. PubMed ID: 14557467
[TBL] [Abstract][Full Text] [Related]
10. Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation.
Bertagna X; Escourolle H; Pinquier JL; Coste J; Raux-Demay MC; Perles P; Silvestre L; Luton JP; Strauch G
J Clin Endocrinol Metab; 1994 Feb; 78(2):375-80. PubMed ID: 8106625
[TBL] [Abstract][Full Text] [Related]
11. Increased serum concentrations of type I procollagen C-terminal propeptide and osteocalcin during a short course of calcitriol administration to adult male volunteers.
Gram J; Bollerslev J; Nielsen HK; Junker P
Acta Endocrinol (Copenh); 1991 Dec; 125(6):609-13. PubMed ID: 1789055
[TBL] [Abstract][Full Text] [Related]
12. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
Martin DE; Blum R; Doto J; Galbraith H; Ballow C
Clin Pharmacokinet; 2007; 46(7):589-98. PubMed ID: 17596104
[TBL] [Abstract][Full Text] [Related]
13. Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological, and hormonal aspects.
Laue L; Lotze MT; Chrousos GP; Barnes K; Loriaux DL; Fleisher TA
J Clin Endocrinol Metab; 1990 Dec; 71(6):1474-80. PubMed ID: 2172280
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study. The GH-2000 Study Group.
Longobardi S; Keay N; Ehrnborg C; Cittadini A; Rosén T; Dall R; Boroujerdi MA; Bassett EE; Healy ML; Pentecost C; Wallace JD; Powrie J; Jørgensen JO; Saccà L
J Clin Endocrinol Metab; 2000 Apr; 85(4):1505-12. PubMed ID: 10770189
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
16. Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes.
Brabnikova Maresova K; Pavelka K; Stepan JJ
Calcif Tissue Int; 2013 Apr; 92(4):354-61. PubMed ID: 23247536
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE
Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the pharmacodynamic effects of deflazacort and prednisolone in healthy subjects.
Babadjanova G; Allolio B; Vollmer M; Reincke M; Schulte HM
Eur J Clin Pharmacol; 1996; 51(1):53-7. PubMed ID: 8880052
[TBL] [Abstract][Full Text] [Related]
20. Prednisone affects inflammation, glucose tolerance, and bone turnover within hours of treatment in healthy individuals.
Kauh E; Mixson L; Malice MP; Mesens S; Ramael S; Burke J; Reynders T; Van Dyck K; Beals C; Rosenberg E; Ruddy M
Eur J Endocrinol; 2012 Mar; 166(3):459-67. PubMed ID: 22180452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
